<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831905</url>
  </required_header>
  <id_info>
    <org_study_id>FOSTINE</org_study_id>
    <nct_id>NCT04831905</nct_id>
  </id_info>
  <brief_title>Micro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINE</brief_title>
  <acronym>FOSTINE</acronym>
  <official_title>Etude de faisabilité de de tolérance d'un Traitement Focal Transrectal Par Micro-ondes de la Tumeur Index Des Patients Ayant un Cancer de la Prostate - FOSTINE 1b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Koelis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the advent of multiparametric MRI (mpMRI), the concept of focal therapy continues to&#xD;
      develop as a compromise between active surveillance and radical tratment. However, it must be&#xD;
      combined with the most stringent quality control measures, such as exceptional Imaging, to&#xD;
      allow close management of the index tumor. the choice of the energy is also crucial. Several&#xD;
      have been tested such as HIFU, electroporation or cryotherapy. A new therapeutic alternative&#xD;
      currently Under investigation resides in the use of microwaves delivered through a thin&#xD;
      needle inserted precisely into the index lesion according to the same procedure as targeted&#xD;
      biopsy under image fusion to induce coagulation necrosis and lead to the tumor destruction.&#xD;
      Through an ablate, performed transrectally under real-time MRI/TRUS image registration and 3D&#xD;
      mapping, in patients with localized prostate cancer (PCa).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a detectable index lesion on mpMRI, PSA level &lt;20 ng/mL and wishing to undergo&#xD;
      a prostatectomy due to significant PCa on biopsy are elibible for this study approved by the&#xD;
      Ethics Committee. Targeted biopsies of the index lesion are performed by using an&#xD;
      ultrasound-MRI image fusion system with Organ based Tracking (OBT)-registration (Trinity*,&#xD;
      KOELIS, France) to provide quality control. Targeted cores are analyzed intraoperatively with&#xD;
      an extemporaneoux analyses. If positive, a targeted focal microwave ablation is achieved&#xD;
      during the same session by a single 18G needle inserted transrectally Under sedation.&#xD;
      Predictive ablation charts obtained with the 2.45 GHZ frequency microwave generator (TATO,&#xD;
      Biomedical Srl, Italy) through ex vivo experiments were used to choose the duration and power&#xD;
      of the treatment.&#xD;
&#xD;
      Treated patients are followed-up for 4 to 6 weeks and the planned radical prostatectomy is&#xD;
      performed. All treated patients complete uroflowmetry test and questionnaires (IPSS,&#xD;
      IPSS-QQL, IIEF-5, and MSHW-EJD-SF) befor, at 7 days and 1 month after the procedure. A mpMRI&#xD;
      of the treated prostate is performed at 7 days after the ablation to identify the&#xD;
      devascularized area, but also to verify that no organ at risk is affected by the microweve&#xD;
      treatment. After radical prostatectomy, whole-mount histology serves to define the ablation&#xD;
      boundaries and dimension in the prostate. It also allows to determine the impact of the use&#xD;
      of microwaves on cancerous tissue. A total of 10 patients will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ablate and resect study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Micro-wave ablation area</measure>
    <time_frame>6 weeks</time_frame>
    <description>Tolerance and faisability of transerectal micro wave ablation of index lesion in prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Micro-wave ablation area</measure>
    <time_frame>6 weeks</time_frame>
    <description>MRI to identify the devascularized area at one week and ablation boundaries and dimensions in the prostate specimen after prostatectomy at one month.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Focal Treatment for Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Pilote study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Micro-wave ablation of index lesion identified on MRi on prostate cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Micro-wave ablation</intervention_name>
    <description>Micro-wave ablation</description>
    <arm_group_label>Pilote study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with detectable index lesion on mpMRI, PSA level &lt;20 ng/mL and wishing to&#xD;
             undergo a prostatectomy due to significant PCA on biopsy.&#xD;
&#xD;
          -  Life expectancy up to 10 years or plus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past history of prostate surgery or pelvic radiotherapy, prostatitis, extra-capsular&#xD;
             extension on MRI or index lesion above 25 mm, distance between rectum and index lesion&#xD;
             less than 5 mm.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre Peltier, MD</last_name>
    <phone>+3225413171</phone>
    <email>alexandre.peltier@bordet.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Peltier, MD</last_name>
      <phone>+3225413171</phone>
      <email>alexandre.peltier@bordet.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>Focal treatment for prostate cancer</keyword>
  <keyword>Focal treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>anonymising patients personal data for publications</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

